India to Lithuania: Mesalamine Export Trade Route
India has recorded 12 verified shipments of Mesalamine exported to Lithuania, representing a combined trade value of $1.2M USD. This corridor is served by 2 active Indian exporters, with an average shipment value of $95.9K USD. The leading Indian exporter is SUN PHARMACEUTICAL INDUSTRIES LIMITED, which accounts for 88% of total export value with 11 shipments worth $1.0M USD. On the buying side, UAB VILNIAUS TRANZITAS is the largest importer in Lithuania with $474.7K USD in purchases. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.
Route Intelligence Overview
The India to Lithuania Mesalamine corridor is one of India's established pharmaceutical export routes, with 12 shipments documented worth a combined $1.2M USD. The route is dominated by SUN PHARMACEUTICAL INDUSTRIES LIMITED, which alone accounts for roughly 88% of all export value, reflecting the consolidated nature of India's mesalamine manufacturing sector.
Across 2 active suppliers, the average shipment value stands at $95.9K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 70% of all shipments, consistent with mesalamine's non-urgent bulk-order profile.
Shipment activity peaks during October-December, with an average transit time of 30 days port-to-port. The route has recorded an annual growth rate of 5%, placing it at rank #15 among India's top mesalamine export destinations globally.
On the import side, key buyers of Indian mesalamine in Lithuania include UAB VILNIAUS TRANZITAS, M/S. UAB VILNIAUS TRANZITAS,, UAB VILNIAUS TRANZITAS and 1 others. UAB VILNIAUS TRANZITAS is the single largest importer with 4 shipments valued at $474.7K USD.
